Table 7. Summary of the prognostic factors in the validation and training cohorts.
| Validation cohort | Training cohort | |||||
| Prognostic factor | Min–Max | Median | N (%) | Min–Max | Median | N (%) |
| Age [years] | 60–85 | 69 | 60–88 | 70 | ||
| Hemoglobine [g/l] | 11–169 | 128 | 15–171 | 126 | ||
| No. of extranodal regions | 0–4 | 1 | 0–5 | 1 | ||
| ECOG score | 0–3 | 1 | 0–4 | 1 | ||
| Ann Arbor stage | 1–4 | 3 | 1–4 | 3 | ||
| Sex (male) | 76 (46.9) | 186 (49.1) | ||||
| Bulky disease (≥7.5 cm) | 58 (35.8) | 136 (35.9) | ||||
| Systemic symptoms present | 63 (39.1) | 138 (37.1) | ||||
| Bone marrow affected | 14 (8.8) | 49 (18.7) | ||||
| LDH (≥ limit) | 98 (62.4) | 226 (60.4) | ||||
| B2M (≥ limit) | 68 (54.4) | 165 (56.5) | ||||
Comparison of the distribution of the prognostic factors in the validation and the training cohorts.